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The inducible costimulator receptor (ICOS) is a third
member of the CD28 receptor family that regulates T
cell activation and function. ICOS binds to a newly iden-
tified ligand on antigen presenting cells different from
the CD152 ligands CD80 and CD86. We used soluble
ICOSIg and a newly developed murine anti-human ICOS
ligand (ICOSL) monoclonal antibody to further charac-
terize the ICOSL during ontogeny of antigen presenting
cells. In a previous study, we found that ICOSL is ex-
pressed on monocytes, dendritic cells, and B cells. To
define when ICOSL is first expressed on myeloid anti-
gen presenting cells, we examined ICOSL expression on
CD34 cells in bone marrow. We found that CD34bright
cells regardless of their myeloid commitment were
ICOSL, whereas ICOSL was first expressed when CD34
expression diminished and the myeloid marker CD33
appeared. However, acute myeloid leukemia cells were
ICOSL-negative, whereas among B-cell malignancies
only some cases of the most mature tumors such as
prolymphocytic leukemia and hairy cell leukemia were
positive. Next, we investigated purified CD34 hemato-
poietic progenitor cells that did not constitutively ex-
press ICOSL but were induced to express ICOSL within
12 h after granulocyte/macrophage colony-stimulating
factor/tumor necrosis factor  (TNF-) stimulation. In-
terestingly, ICOSL was induced prior to CD80/CD86 in-
duction on CD34 cells so that ICOSL was expressed in
the absence of CD80/CD86. This suggests that ICOSL is
an early differentiation marker along the monocytic/
dendritic maturation pathway. Induction of ICOSL was
dependent on TNF- and was regulated via NF-B as
revealed by use of inhibitors specific for IB phospho-
rylation such as BAY 11-7082 and BAY 11-7085. The an-
tigen presenting capacity of TNF- stimulated CD34
cells was strongly inhibited by ICOSIg fusion proteins
or by NF-B inhibition. Thus, TNF--induced ICOSL ex-
pression seemed to be functionally important for the
costimulatory capacity of CD34 hematopoietic progen-
itor cells.
Successful antigen-specific T cell stimulation via the T cell
receptor (TCR)1-CD3 complex (TCRCD3) requires costimula-
tory signals by the CD28 receptor family. During this process,
CD28 or CD152 (CTLA-4) expressed on T cells is engaged by
the ligands CD80 (B7-1) or CD86 (B7-2) expressed on antigen
presenting cells (1, 2). The inducible costimulator (ICOS) is a
recently defined third member of the CD28 family, but unlike
CD28, it is not constitutively expressed on T cells (3). ICOS
expression requires the activation of T cells via the TCRCD3
complex. ICOS shows structural homology to CD28 and CD152,
but it differs in the MYPPPY homology domain necessary for
binding of CD28/CD152 to CD80 or CD86 (4). Engagement of
ICOS, like CD28, can mediate potent costimulation of T cells (3,
5), and promotes T cell proliferation at levels similar to those
observed after CD28 triggering but without the accompanying
increase in IL-2 production. Instead, ICOS up-regulates ex-
pression of IL-4, IL-5, GM-CSF, IFN-, TNF-, and IL-10 (3, 6).
Blocking the interaction of ICOS with its natural ligand by use
of a soluble ICOSIg construct reduced the proliferative re-
sponse of T cells (7). The expression of ICOS on T cells varies
depending on the source of lymphoid tissue; T cells in tonsillar
germinal centers express high levels of ICOS, suggesting a role
in the regulation of germinal center B cell differentiation (3).
Among the ligands of the CD28 receptor family, CD80 is
expressed on antigen presenting cells after induction by mi-
crobes, cytokines, or CD40 ligation and is also expressed on
fibroblasts, whereas CD86 is constitutively expressed on mono-
cytes and is inducible upon stimulation (8). Most lymphoma
and leukemia cells lack CD80, but50% of cases express CD86
(9). Recently, new homologues of CD80 and CD86 were de-
scribed. One of these, B7h (also designated B7RP-1, GL50, or
B7-H2) binds to ICOS but not to CD28 or CD152/CTLA-4 (5,
10–14). The ligand for ICOS (ICOSL) belongs to the immuno-
globulin family of genes, but shares only 20% amino acid
identity with CD80 and CD86. ICOSL is constitutively ex-
pressed on B cells, macrophages, and on murine spleen cells
and can be induced by TNF- or by inflammatory stimuli on
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fibroblasts and peripheral tissue (5, 10, 13–14). TNF- is a
potent inflammatory cytokine that upon stimulation of TNF
receptors leads to activation of transcription factors such as
NF-B/Rel (15, 16). Expression of ICOSL has been shown to
provide costimulation in vitro and enhance T cell-dependent
antibody responses and cytokine production from CD4 T cells
in vivo (3, 5, 17). Moreover, recent results reveal that blockade
of ICOS/ICOSL interaction also inhibits TH1-regulated effector
phases in acute allograft rejection and experimental induction
of autoimmune encephalomyelitis, leading to increased al-
lograft acceptance and prevention of the disease (18, 19). In
addition, it appears that ICOS stimulation also has a promi-
nent role in secondary cytotoxic CD8 T cell responses, leading
to effective mobilization of adoptively transferred T cells (20).
We reported previously that ICOSL is expressed on antigen
presenting cells and can be up-regulated by IFN- but not
TNF- on monocytes, whereas expression levels remain con-
stant on monocyte-derived dendritic cells (DC) (7). In this
study, we have used soluble ICOSIg and a recently developed
monoclonal antibody against human ICOSL to further charac-
terize its expression, function, and regulation in bone marrow
and CD34 progenitor cells when differentiated into dendritic
cells.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents—U937 cells (monocytic) were cultured as
described (7). Actinomycin D, cycloheximide, the inhibitors of IB
phosphorylation: 3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY
11-7082) and 3-[(4-t-butylphenyl)-sulfonyl]-2-propenenitrile (BAY 11-
7085) (21) were purchased from Calbiochem (Schwalbach, Germany).
The NF-B inhibitor pyrrolidine dithiocarbamate (PDTC) (22) and 12-
O-tetradecanolphorbol-13-acetate (TPA) were purchased from Sigma
(Deisenhofen, Germany).
Monoclonal Antibodies and Production of ICOSIg Fusion Protein—
Allophycocyanin (APC)- or phycoerythrin (PE)-conjugated monoclonal
antibodies against CD1a (SK9), CD3 (SK7), CD4 (SK3), CD11c (S-HCL-
3), CD13 (L138), CD14 (MP9), CD15 (MMA), CD19 (4G7), CD20 (L27),
CD22 (S-HCL-1), CD33 (P67.6), CD34 (8G12), CD38 (HB-7), CD56
(My31), CD80 (L307.4), HLA-DR (L243), and isotype control mAb
(MOPC-21) were purchased from Becton Dickinson (Heidelberg,
Germany). Antibodies against CD83 (HB15a) and CD86 (FUN-1) were
from Coulter Immunotech and PharMingen (both Hamburg, Germany),
respectively. The ICOSIg and CD152Ig fusion proteins were produced
as described previously (7). Briefly, stable Chinese hamster ovary lines
expressing ICOSIg or CD152Ig were grown in Excell 302 Chinese
hamster ovary media (JRH Biosciences, Lenexa, KS) containing 0.5
mg/ml recombinant insulin (Life Technologies, Inc.), sodium pyruvate
(Irvine Scientific, Santa Ana, CA), 4 mM L-glutamine (Irvine Scientific),
23 nonessential amino acids for minimal essential medium (Irvine
Scientific), and 100 nM methotrexate (Sigma). Spent supernatants were
harvested from large scale cultures, and Ig fusion proteins were puri-
fied by protein A affinity chromatography over a 2-ml protein A-agarose
column (Repligen, Cambridge, MA). Fusion protein was eluted from the
column as 0.8-ml fractions in 0.1 M citrate buffer (pH 2.7) and neutral-
ized using 100 ml of 1 M Tris-HCl (pH 7.4). Eluted fractions were
assayed for absorbance at 280 nm, and fractions containing fusion
protein were pooled, dialyzed overnight in several liters of PBS (pH 7.4),
and filter-sterilized through 0.2-m syringe filter units (Millipore,
Bedford, MA). Staining capacity was tested by serial dilutions on U937
cells that have been shown to be positive for ICOSIg and CD152Ig
binding. Optimal staining was usually obtained with 1–2 g of fusion
protein/106 cells.
Preparation of Bone Marrow and Isolation of CD34 Cells—Bone
marrow cells were collected after informed consent from patients with
breast cancer or non-Hodgkin’s lymphoma undergoing evaluation for
bone marrow involvement and found to be negative. Cells were isolated
by Ficoll-Hypaque (Seromed, Berlin, Germany) density gradient cen-
trifugation. Interphases were harvested and washed three times and
subjected directly to flow cytometry analysis. For positive selection of T
cells, B cells, and CD33 and CD34 cells from bone marrow, cells were
labeled with anti-CD3 mAb (SK7), anti-CD19 mAb (HD37), anti-CD33
mAb (P67.6), or anti-CD34 (My10), respectively and then positively
selected with goat anti-mouse IgG immunomagnetic beads according to
the manufacturer’s instructions (Dynal, Hamburg, Germany). Purity
was greater than 95%, as assessed by flow cytometry.
For purification of CD34 cells for dendritic cell differentiation as-
says, mononuclear cells were collected by leukapheresis from periph-
eral blood of breast cancer patients in the context of a high dose
chemotherapy program using an AS104 cell separator (Fresenius, Wies-
baden, Germany). CD34 cells were enriched by use of an Isolex 300
device (Baxter Biotech, Mu¨nchen, Germany) as described previously
(23). The positively selected cell fraction (purity  90%) was cryopre-
served and stored within the vapor phase of liquid nitrogen.
Stimulation of CD34 Cells and Allogeneic Mixed Lymphocyte Reac-
tion (MLR)—For stimulation CD34 cells were plated in six-well Nun-
clon plates (Nunc, Naperville, IL) at a density of 1 106 cells/ml in 2 ml
of RPMI 1640 medium with L-glutamine, 2-mercaptoethanol, antibiot-
ics, and 10% fetal calf serum. Culture medium was supplemented with
different cytokines at the following concentrations depending on the
stimulation mixture used: 100 ng/ml human GM-CSF (Leukomax®,
Novartis), 1000 units/ml human IL-4 (kindly provided by Dr. Satwant
Narula, Schering Plough Research Institute, Kenilworth, NJ), 50 ng/ml
human TNF- (Bender, Vienna, Austria), and 1000 units/ml human
IL-3 (R&D Systems, Wiesbaden, Germany). Every other day, 50% of the
medium was removed and the same volume of fresh medium containing
twice the amount of cytokines was added. Cells were analyzed at dif-
ferent time points for differentiation markers and for ICOSIg or
CD152Ig binding.
Responder T cells for the MLR were obtained from normal donors
after centrifugation over Ficoll-Hypaque and subsequent positive selec-
tion via CD4 positive isolation kit with immunomagnetic beads accord-
ing to the manufacturer’s instructions (Dynal). To induce ICOS expres-
sion, CD4 T cells (purity  95%) were preactivated before use in the
MLR by soluble anti-CD3 (OKT3, Ortho Pharmaceuticals, Raritan, NJ)
for 12 h at 37 °C at a concentration that does not induce proliferation
(0.5 g/ml).
MLRs were set up by culturing 5  103 -irradiated CD34 cells
(3,000 rad 137Cs) that had been precultivated for 12 h under the condi-
tions indicated in the results, with 5  104 prestimulated CD4 T cells.
Cells were cocultured in 96-well round-bottom microtiter plates for 3
days. T cell proliferation was assessed after addition of 1 Ci/well
[3H]-thymidine (Amersham Pharmacia Biotech, Freiburg, Germany) for
the final 9 h. [3H]-Thymidine incorporation was measured by liquid
scintillation counting. All determinations were performed in triplicate
and measured as the mean counts/min  S.E.
Hematologic Malignancies—Tumor cells were obtained after in-
formed consent from freshly diagnosed or cryopreserved samples of
patients with acute and chronic leukemia or follicular non-Hodgkin’s
lymphoma undergoing routine phenotype analysis. All lymphoma cases
were leukemic, and cell populations contained at least 75% neoplastic
cells according to FACS analysis. Lymphoma diagnoses had been inde-
pendently confirmed by routine histology; acute myeloid leukemia
(AML), acute lymphoblastic leukemia, chronic lymphocytic leukemia,
hairy cell leukemia, and prolymphocytic leukemia cases had been diag-
nosed by a combination of standard morphology, histochemistry, and
phenotype analysis. All the AML cases were positive for CD13 and/or
CD33; all B cell leukemias and lymphomas were positive for CD19.
RNA Preparation and Polymerase Chain Reaction (PCR)—For re-
verse transcription-PCR (RT-PCR), cells were lysed in Trizol® (Life
Technologies, Karlsruhe, Germany), RNA prepared and converted to
first strand cDNA by use of random hexamer or oligo(dT) primers and
murine leukemia virus reverse transcriptase (PerkinElmer Life Sci-
ences, Weiterstadt, Germany) according to the manufacturer’s instruc-
tions. Success of cDNA synthesis was monitored by PCR with 2-
microglobulin-specific primers 5-CCAGCAGAGAATGGAAAGTC-3
and 5-GATGCTGCTTACATGTCTCG-3, amplifying after 27 cycles a
PCR product of 268 base pairs in size. Primers used for analysis of
ICOSL expression were derived from B7-H2 sequence (GenBank ac-
cession no. AF289028; Ref. 13) and were 5-GGTTACACTGCATGTG-
GCAGC-3 and 5-GTGAGCTCCGGTCAAACGTGG-3. PCR synthesis
was run for 40 cycles, amplifying a 534-base pair product.
Electromobility Shift Assay (EMSA)—For isolation of nuclear pro-
teins, 2  106 CD34 cells were washed in cold PBS before addition of
200 l of cold low salt buffer (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1
mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethyl-
sulfonyl fluoride, 2 M leupeptin). After a 15-min incubation on ice, 12
l of 10% Nonidet P-40 was added and samples were vortexed. Nuclei
were spun down and resuspended in 25 l of high salt buffer (20 mM
HEPES (pH 7.9), 25% (v/v) glycerol, 0.4 M NaCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 2 M
leupeptin). For extraction of proteins, samples were vigorously rocked
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at 4 °C for 20 min. After subsequent centrifugation, nuclear extracts
were collected as supernatants and stored at 80 °C until use. The
NF-B oligonucleotide (Santa Cruz Biotechnology, Heidelberg,
Germany) was end-labeled with [-32P]ATP (Amersham Pharmacia
Biotech) in the presence of T4 polynucleotide kinase (Promega, Mann-
heim, Germany). Unincorporated [-32P]ATP was removed by a NICK
Sephadex column (Amersham Pharmacia Biotech). Binding reactions
were performed for 30 min on ice with 3 g of protein and 20,000 cpm
of radiolabeled NF-B oligonucleotide in 20 l of binding buffer (4%
Ficoll, 20 mM HEPES (pH 7.9), 50 mM KCl, 1 mM EDTA, 1 mM dithio-
threitol, 1 mM phenylmethylsulfonyl fluoride, 0.25 mg/ml bovine serum
albumin). The DNA-protein complexes were then separated from un-
bound oligonucleotides on nondenaturing 4.5% polyacrylamide gels in
0.5 TBE buffer, fixed, and analyzed using a PhosphorImager (Molec-
ular Dynamics, Sunnyvale, CA).
Flow Cytometry Analysis—As described previously (7), cells were
incubated in staining buffer (2% fetal calf serum in PBS, 0.05% NaN3),
nonspecific Fc-binding was blocked by preincubation with mouse anti-
human CD32 F(ab)2 antibody (Ancell, Bayport, MN) at 1 g/ml for 30
min at 4 °C. When evaluating AML cells, it was important to use
human Ig to block nonspecific Fc receptor binding, as CD32 antibody
treatment was not sufficient because of high expression of other Fc
receptors in AML cells. After Fc blocking, cells were washed once in
staining buffer and incubated 45 min on ice with 10 g/ml Ig fusion
protein. Cells were again washed once with binding buffer and subse-
quently incubated with second step reagent FITC-conjugated goat anti-
human IgG F(ab)2 (Jackson) at 1:50 dilution for 45 min on ice. Finally
cells were washed three times in staining buffer, resuspended in
PBS, and analyzed on a FACScalibur (Becton Dickinson, Heidelberg,
Germany). For staining of DC generated from CD34 cells, APC- and/or
PE-conjugated mAbs directed against CD1a, CD3, CD4, CD11c, CD14,
CD15, CD33, CD34, CD38, CD54, CD58, CD80, CD83, CD86, HLA-DR,
and their corresponding isotype controls (Becton Dickinson, Mountain
View, CA) were used. In addition, for two/three-color immunofluores-
cence of bone marrow and CD34 cells, cells were preblocked with 50
g/ml human Ig (Biotest Pharma, Dreieich, Germany) instead of CD32
antibody and stained with a murine mAb against the extracellular
domain of human ICOSL developed with the help of Genovac (Freiburg,
Germany).
RESULTS
CD34bright Hematopoietic Progenitor Cells in Human Bone
Marrow Are ICOSL-negative—Previously, we found that the
ligand of ICOS (ICOSL) is expressed on antigen presenting
cells of myeloid origin and on 40% of peripheral blood CD19
B cells (7). In this study we wanted to determine whether
ICOSL is expressed early during ontogeny of myeloid antigen
presenting cells. Human bone marrow mononuclear cells were
isolated and stained with mouse anti-human ICOSL mAb fol-
lowed by goat anti-mouse FITC, and then counterstained with
APC- and PE-conjugated mAb. Fig. 1 shows the staining of
ICOSL on CD34-positive cells according to their CD33 expres-
sion. When gating on the small lymphoid cells in the bone
marrow (Fig. 1A, upper part), almost all cells were ICOSL-
negative. Only a few cells in this population coexpress CD33. In
total bone marrow, a large proportion of the CD34 cells coex-
pressed CD33 (Fig. 1A, lower half). Only the CD34dullCD33
fraction (R9 in Fig. 1A) showed some staining for ICOSL (25 
4%), suggesting that ICOSL expression is acquired as soon as
hematopoietic progenitor cells have a clear myeloid commit-
ment, as indicated by strong CD33 expression and beginning
loss of CD34 antigen expression. The amount of CD34CD38
cells in our preparations was too small to allow for a clear
evaluation of ICOSL expression on this fraction of more prim-
itive hematopoietic precursor cells (data not shown).
We also examined ICOSL expression on purified bone mar-
row fractions by RT-PCR. We isolated bone marrow cells ac-
cording to their expression of CD34 and lineage markers for B
cells, T cells, and myeloid cells by immunomagnetic separation
for CD34, CD19, CD3, and CD33, respectively. Primers for
RT-PCR were designed from the sequence of the B7-H2 gene to
which protein binding of ICOSIg recently has been shown (13).
Calibrated cDNA of purified cell populations (see “Experimen-
tal Procedures”) confirmed the lack or very weak expression in
the CD34bright fraction that was isolated and revealed a clear
presence of the ICOSL transcript in the CD33 myeloid cells
and in the CD19 B cell population, consistent with the ICOSL
expression on peripheral blood cells (Fig. 1B). The weak expres-
FIG. 1. ICOSL expression in the bone marrow. A, for three-color
FACS analysis, a newly developed murine anti-human-ICOSL mAb
was used and detected by goat anti-mouse FITC (see “Experimental
Procedures”), followed by counterstaining with directly labeled
CD34-PE and CD33-APC. Different populations identified by their level
of CD33 and CD34 expression were gated (left), and their ICOSL ex-
pression is shown (right). Quadrant settings were done with respective
isotype controls. In the upper half, the small lymphocyte gated popula-
tion is shown; the lower half represents staining for total bone marrow.
B, RT-PCR of bone marrow subpopulations for ICOSL expression (up-
per panel). CD3, CD19, CD33, and CD34 subpopulations were
isolated with immunomagnetic beads. Expression was compared with
whole bone marrow (BM);  is PCR control without cDNA. Use of
approximately equal amounts of cDNA in each case was monitored with
2-microglobulin (2M)-specific PCR (lower panel).
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sion of ICOSL transcripts in the CD3 T cell fraction is con-
sistent with a weak expression on a small number of T cells by
flow cytometry (data not shown) and deserves further investi-
gation. Thus, the lack of ICOSL staining on CD34brightCD33
and CD34brightCD33cells suggested that hematopoietic pro-
genitors do not express the ligand for ICOS and that its expres-
sion is acquired later during differentiation into myeloid com-
mitted CD34dull/CD33bright cells.
Leukemic Cells Corresponding to Immature Myeloid and
Lymphoid Cells Do Not Express ICOSL—We reasoned that
ICOSL is first acquired when hematopoietic cells differentiate
into antigen presenting cells of myeloid (monocytes and DC) or
lymphoid (B cells) origin. Because the phenotype of leukemia
and lymphoma cells may correspond to frozen stages of lymph-
oid and myeloid differentiation, we examined leukemic cells for
ICOSIg binding. None of seven cases of CD13CD33 AML nor
any of six cases of B-lineage acute lymphoblastic leukemia
examined was bound by ICOSIg (Table I). These data suggest
that the very early myeloid cells and B cell progenitor cells do
not express ICOSL. Surprisingly, some of the leukemias
stained positive for CD80 and/or CD86. Four of five cases of
chronic lymphocytic leukemia, which is thought to represent a
disease of immature, virgin B-lymphocytes, were ICOSL,
whereas two of four prolymphocytic leukemia and four of six
hairy cell leukemia were ICOSL. Because both prolympho-
cytic leukemia and hairy cell leukemia correspond to mature,
almost preterminally differentiated B cells, the results suggest
that ICOSL is expressed relatively late during B cell matura-
tion. None of seven cases of follicular lymphoma (which corre-
spond to germinal center B cells) reacted with our ICOSIg
reagent.
ICOSL Is Expressed Early during Differentiation of CD34
Progenitor Cells into Dendritic Cells—Although ICOSL is ab-
sent from CD34bright hematopoietic progenitor cells, it is pres-
ent on mature monocytes and dendritic cells. Therefore, we
evaluated ICOSL expression during in vitro maturation of pu-
rified CD34 cells. These cells were enriched from mobilized
peripheral blood progenitor cells by immunomagnetic separa-
tion. The CD34 population obtained with this procedure is
more uniform than the heterogeneous CD34 population in the
bone marrow, according to forward scatter and side scatter
profiles and marker expression. All cells were uniformly bright
CD34-positive, CD38-positive, and weakly CD33-positive (Fig.
2, A and B). Cells were grown in the presence of different
cytokine mixtures including GM-CSF/TNF-, GM-CSF/IL-4/
TNF-, and GM-CSF/IL-3. The combination of GM-CSF and
TNF- induces differentiation of hematopoietic progenitor cells
into DCs (24). IL-4 prevents terminal monocytic differentia-
tion, allowing for generation of large numbers of DC even from
mature monocytes (25, 26). Purified CD34 cells were culti-
vated for 12 days and analyzed at day 3, 6, 9, and 12 for surface
marker expression (Table II). At day 9 DCs differentiated from
CD34 cells in the presence of GM-CSF and TNF- were pos-
itive for CD11c, CD33, CD54, CD58, CD80, CD86, and HLA-
DR; in part positive for CD1a and CD14; and negative for CD15
TABLE I
ICOSL versus CD80⁄CD86 expression on leukemias and lymphomas
AML indicates acute myelogenous leukemia; B-ALL, lymphoblastic
leukemia of B cell origin; B-CLL, B cell type chronic lymphocytic leu-
kemia; B-PLL, B cell type prolymphocytic leukemia; HCL, hairy cell
leukemia; FL, follicular lymphoma. The cell populations contained
more than 75% malignant cells.
Tumor type Marker CD80a CD86a ICOSLa
AML CD13/CD33 0/7 3/7 0/9
B-ALL CD19 1/6 5/6 0/6
B-CLL CD19 0/5 2/5 1/5
B-PLL CD19 1/4 2/4 2/4
HCL CD19 2/6 3/6 4/6
FL CD19 1/7 3/7 0/7
a Number of positive cases/cases tested.
FIG. 2. Differentiation of CD34 progenitor cells into dendritic
cells results in early up-regulation of ICOSL. A, purified CD34
cells from mobilized peripheral stem cells were cultured with GM-CSF/
TNF-, GM-CSF/IL4/TNF-, or GM-CSF/IL-4/TNF- until day 3, fol-
lowed for another 3 days by GM-CSF/TNF- (see text) to induce differ-
entiation into dendritic cells. Kinetic studies of FACS phenotype were
analyzed on days 0, 3, and 6 (B). To identify the ICOSL-inducing
cytokine on purified CD34 cells, cells were cultivated for 18 h with
G-CSF, GM-CSF, or TNF-, respectively. FACS analysis after 18 h was
performed with murine anti-human ICOSL mAb detected by goat anti-
mouse FITC and counterstained with APC- or PE-conjugated mAbs (see
“Experimental Procedures”). A fraction of the cells was further culti-
vated to confirm terminal differentiation of DC (see “Results,” Table II).
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(Table II, and data not shown). CD83 expression was achieved
only after the 6th day of culture (Table II).
DC and monocyte populations can be distinguished by the
expression of CD11c and CD14 (24, 27). Therefore, we exam-
ined ICOSL expression together with CD11c and CD14. ICOSL
was equally expressed in the GM-CSF/TNF--induced
CD11cCD14 DC and CD11cCD14 monocyte fraction (Fig.
2A). Both at day 3 and day 6, cells cultured in GM-CSF, TNF,
and IL-4 had a lower expression of ICOSL as compared with
cells cultured with GM-CSF and TNF, suggesting that IL-4
partially counteracted the induction of ICOSL and reduced the
percentage of ICOSL by 30–40%. However, this effect was
reversible when IL-4 was washed out at day 3 and replaced by
GM-CSF/TNF- for another 3 days and measured again at day
6 (Fig. 2A). Significant expression of the costimulatory mole-
cules CD80/CD86 (as judged by binding of the CD152Ig fusion
protein (or anti-CD80 and CD86 mAb; data not shown) ap-
peared later at day 6 (Table II) and were not affected by IL-4
(data not shown). The expression of ICOSL on maturating DC
peaked at day 3 of the culture and was not further up-regulated
later (Table II).
Having shown that the combination of GM-CSF and TNF
strongly induces the expression of ICOS ligand in culture, we
then evaluated which cytokine is responsible for this effect;
TNF- appears to be the crucial cytokine for induction of ex-
pression of ICOSL, whereas GM-CSF alone and G-CSF alone
were not able to induce ICOSL expression (Fig. 2B). Interest-
ingly, the TNF-mediated ICOSL induction on purified CD34
cells was already observed as early as 18 h of culture. All
CD34 cells coexpressed CD38, a marker that is not expressed
on rare more primitive CD34-positive hematopoietic progenitor
cells. In comparison with GM-CSF and G-CSF alone, TNF-
increased the expression of both ICOSL and CD11c, whereas
cells remained negative for CD14 expression within this time.
Dendritic cells distinctive from those that give rise to Lange-
rhans cells can be generated by stimulation with IL-3 or IL3 
GM-CSF (28). These cells are also called “lymphoid dendritic
cells” and are positive for CD4, CD33, CD54, CD58, CD86, and
HLA-DR, but negative for CD1a and CD80 (Table II, and data
not shown). The combination of GM-CSF and IL-3 induced an
up-regulation of ICOSL that was earlier and stronger as com-
pared with CD80/CD86 (Table II). Highest ICOSL expression
however was achieved at a later time than in TNF-containing
cultures. Moreover, expression of CD14 and CD83 was consis-
tently lower in GM-CSF/IL-3-stimulated cells.
The TNF-induced Up-regulation Is Mediated via NF-B Ac-
tivation—Twelve hours after stimulation with TNF- alone,
CD34 cells expressed high levels of ICOSL (Fig. 3A). The
rapid and strong induction of ICOSL on CD34 cells by TNF-
cannot be explained simply by release of ICOSL from intracel-
lular stores, because inhibitors of de novo protein or RNA
synthesis, such as cycloheximide or actinomycin D, completely
abrogated ICOSL expression (Fig. 3A). More striking was the
complete suppression of TNF--induced ICOSL by the inhibi-
tors of NF-B-mediated signal transduction PDTC and, in par-
ticular, BAY 11-7082 and BAY 11-7085 (which interfere with
NF-B by inhibiting IB phosphorylation) strongly inhibited
TNF--induced ICOSIg binding. BAY 11-7082 and 11-7085
were already effective at a low dose level of 2 M. To demon-
strate that the strong suppression of TNF--induced ICOSL on
CD34 cells by these inhibitors indeed affects NF-B-mediated
transcription, we performed EMSAs of these cells. The EMSAs
emphasized a strong TNF-mediated induction of NF-B that
was completely blocked by the inhibitors BAY 11-7085 (Fig.
3B). Subsequently, a complete suppression of TNF-induced
ICOSL transcription by BAY 11-7085 was also observed by
RT-PCR (Fig. 3C). Although we cannot formally exclude that
these inhibitors affect other pathways, the up-regulation of
ICOSL on CD34 cells seemed to be mainly dependent on the
NF-B pathway, because we tested various other inhibitors of
protein kinases and mediators of TNF-induced signal transduc-
tion (inhibitors of protein kinase C (staurosporine, Ro318220,
and CGP41251) inhibitors of mitogen-activated protein kinase
pathways such as U0126, an inhibitor of the extracellular sig-
nal-regulated kinase pathway (mitogen-activated protein ki-
nase/extracellular signal-regulated kinase kinase 1/2 inhibi-
tor), and the p38 mitogen-activated protein kinase inhibitors
SB203580 and SB202190, inhibitors of tyrosine phosphoryla-
tion such as genistein, inhibitors of G protein signaling such as
NF023, and inhibitors of phospholipase A2 such as methyl
arachinodyl fluorophosphonate, all of which were negative in
our experimental setting but active on control cells or in differ-
ent stimulation assays. Furthermore, comparable amounts of
the solvents of the different inhibitors had no influence on the
TNF-mediated induction of ICOSL on CD34 cells (data not
shown).
TNF-activated CD34 Cells Are Potent Stimulators of Allo-
geneic T Cells in MLR—To assess the possible function of
ICOSL during early differentiation of myeloid antigen present-
ing cells, we tested the stimulatory capacity of ICOSL cells in
allogeneic MLRs with purified CD4 T cells in the presence or
absence of ICOSIg (Fig. 4). T cells had been prestimulated with
TABLE II
ICOSL expression during DC differentiation
Values are given as percentage  standard deviation.
Day 0 Day 3 Day 6 Day 9 Day 12
GM-CSF/TNF
CD1a 2.9  2.8 1.7  2.0 11.9  5.4 24.3  12.1 18.0  6.7
CD11c 40.3  4.5 67.3  26.9 86.7  5.4 92.4  3.7 94.4  1.8
CD14 2.7  2.5 1.4  1.0 19.6  8.8 34.0  10.0 32.4  14.8
CD33 73.3  28.0 85.2  14.1 82.8  10.6 68.7  5.9 84.7  12.5
CD83 0.5  0.5 8.5  5.0 4.4  1.5 26.7  21.8 11.9  2.2
HLA-DR 98.3  0.5 95.5  0.2 94.7  2.3 96.1  0.6 94.6  2.2
ICOSIg 2.6  2.0 65.0  6.6 56.6  17.9 66.2  6.6 40.6  5.9
CD152Ig 0.9  1.2 9.8  3.0 37.5  10.9 57.2  2.5 65.4  3.8
GM-CSF/IL-3
CD1a 2.9  5.0 9.5  9.8 9.8  8.5 1.6  1.2
CD11c 53.2  11.9 70.4  1.6 90.8  2.2 86.9  4.4
CD14 0.5  1.6 10.6  6.6 13.6  14.5 8.1  1.1
CD33 87.6  2.3 92.3  4.3 89.8  2.1 93.5  3.1
CD83 5.2  2.5 10.7  9.7 3.6  4.5 1.9  3.5
HLA-DR 92.9  2.2 95.6  1.0 93.6  1.5 69.9  13.3
ICOSIg 26.9  18.1 38.7  4.4 52.4  19.2 42.1  14.9
CD152Ig 7.7  5.8 24.8  1.6 32.1  6.3 63.7  5.6
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FIG. 3. ICOSL induction on CD34 progenitor cells is mediated
via NF-B activation. A, TNF- alone induces ICOSL expression on
purified CD34 cells as measured by FACS analysis with ICOSIg to-
gether with FITC-conjugated goat anti-human IgG F(ab)2 (upper pan-
el). For inhibition assays CD34 cells were pretreated for 30 min with
the different inhibitors shown and subsequently stimulated for another
12 h with TNF- in the presence of the inhibitors. ICOSL induction on
CD34 cells by TNF- required de novo protein (cycloheximide) or RNA
(actinomycin D) synthesis. Complete suppression of ICOSL expression
is observed in the presence of inhibitors of the NF-B-mediated signal
transduction BAY 11-7082, BAY 11-7085, and PDTC. B, inhibition of
TNF--induced NF-B binding in the nuclear extracts of CD34 cells by
the compound BAY 11-7085 as revealed by EMSA. C, inhibition of
TNF-- or TPA-induced ICOSL-expression by 2 M BAY 11-7085 shown
at the transcriptional level by RT-PCR (upper panel). Use of approxi-
mately equal amounts of cDNA in each case was monitored with 2-
microglobulin (2M)-specific PCR (lower panel).
FIG. 4. ICOS:ICOSL interaction is involved in the allostimula-
tory capacity of TNF-activated CD34 cells. A, purified CD34
cells, which were used as stimulator cells in MLR assays, were pre-
treated for 18 h with TNF- and stained for ICOSL, CTLA4Ig binding,
and HLA-DR expression (upper panel). Additional phenotypic markers
are shown in Fig. 2B. Purity of CD4 T cells is shown (lower panel). B,
for MLR assays CD34 cells were pretreated for 18 h with TNF- or
medium alone in the presence (lower panel) or absence (upper panel) of
the NF-B specific inhibitors BAY 11-7082 or BAY 11-7085 (TNF 
Inhib.). Purified CD4 T cells were pretreated with soluble anti-CD3.
Cells were washed and then cocultured for 3 days in the presence or
absence of different Ig constructs. Cells without TNF pretreatment ()
do not stimulate in the MLR. Data are shown as stimulation index 
S.E. One of four different experiments is shown.
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CD3 to induce ICOS expression, because ICOS is not constitu-
tively expressed on T cells. The dose of CD3 antibody used was
not sufficient to induce T cell proliferation (data not shown).
CD34 cells were pretreated 12 h with TNF- in the presence
or absence of the NF-B-specific inhibitors BAY 11-7082 or
BAY 11-7085. At this point, CD34 cells stimulated with TNF
expressed HLA-DR and ICOSL, but not CD80/86 (Fig. 4A).
Moreover, at this time point, TNF-stimulated CD34 cells ex-
press CD38 and lack CD14 (Fig. 2B). Cells were then washed,
irradiated, and cocultured with T cells for 3 days in the pres-
ence or absence of a blocking dose of ICOSIg or CD152Ig,
shown previously to block proliferation of allogeneic CD4 T
cells (7). As expected, ICOSIg reduced T cell proliferation to
background levels (Fig. 4B, upper panel), whereas inhibition of
CD80/86:CD28 interaction by CD152Ig in this situation was
less effective. Indeed, we reproducibly observed some degree of
inhibition by CD152Ig, which may be a result of the fact that
during the coculture some degree of up-regulation of CD80/
CD86 expression does occur despite irradiation. A consistent
amount of inhibition (50%) was also observed by preventing
ICOSL expression via NF-B-specific inhibition (Fig. 4B, lower
panel). Together, these results suggest that the TNF-mediated
ICOSL induction on CD34 cells delivers a costimulatory sig-
nal to allogeneic T cells.
DISCUSSION
In this study we have further characterized the expression of
the ligand of the newly described costimulatory molecule ICOS
during differentiation of antigen presenting cells and compared
its expression to that of the other costimulatory ligands CD80
and CD86. ICOSL is not present on CD34bright hematopoietic
precursor cells, but is acquired later during ontogeny of both
myeloid antigen presenting cells and B lymphocytes. In con-
trast, both AML and acute lymphoblastic leukemia cases were
also found to be negative; only a few leukemia cases with the
phenotype of most mature B lymphocytes were ICOSL. Fur-
thermore, it is surprising that all seven cases of leukemic
follicular lymphoma cases tested were ICOSL.
The prominent role of ICOSL in B cell responses has been
demonstrated in transgenic mice overexpressing soluble
ICOSL (5). In addition, ICOS-deficient mice show severely im-
paired T cell-dependent B cell responses and germinal center
formation (29–31). In our previous paper we found a heteroge-
neous ICOSL distribution in lymphoma cell lines of different
maturation stages, so altogether it is unlikely that in B cells
ICOSL expression directly correlates with the maturation
stage of B cells. However, the same appears to be true for CD80
and CD86.
Along the differentiation pathway of CD34 cells toward the
monocytic/dendritic lineage, ICOSL appears on cells as early as
12 h after stimulation with TNF-. It is not further up-regu-
lated during terminal differentiation of dendritic cells. We have
found that IL-4 down-regulates the TNF-mediated ICOSL ex-
pression, an effect that seems to be reversible. This may be part
of a regulatory loop, because ICOS expression on T cells ap-
pears to be crucial for IL-4 secretion (29) and will be a matter
of further investigation. Although TNF is a crucial stimulus to
induce ICOSL, as shown by stimulation with TNF- or GM-
CSF/TNF-, GM-CSF/IL-3 was also relatively effective at stim-
ulating ICOSL expression, although ICOSL expression peaked
at a later time point. It has been proposed that this cytokine
mixture differentiates CD34 cells into “lymphoid” DCs (28). If
this is the case, then ICOSL apparently is expressed on both
myeloid and lymphoid DCs. However, we cannot formally ex-
clude the possibility that, during the culture period, TNF- was
somehow produced, thereby providing an indirect source of
ICOSL induction. In all these cultures, up-regulation of ICOSL
was consistently observed much earlier than for the CD152Ig
binding molecules CD80/CD86. The functional reason for this
is not yet clear. One intriguing possibility is that there are
ICOS cells in the bone marrow, which can be influenced by
maturing myelo-monocytic cells via ICOS-ICOSL interaction, a
possibility we are currently exploring.
The early expression of ICOSL during myeloid ontogeny/
differentiation of antigen presenting cells is rather unique
among costimulatory molecules; Rondelli and co-workers (32)
reported that CD86 is expressed constitutively on a small sub-
set (6%) of CD34 human marrow cells. Subsequently Ryn-
carz et al. (33) showed that CD34CD86 cells are committed
precursors of macrophages and dendritic cells that have al-
ready lost the ability to differentiate into granulocytes. In
CD34CD86 cells, CD86 started to appear within 2 days in
the presence of TNF- and stem cell factor with a peak of
expression after 6 days. Our CD34-enriched fraction was neg-
ative for CD152 binding at the beginning of the culture. This
could be a result of the different source of CD34 cells in our
experiments; we used peripheral blood-derived CD34 cells,
which may reflect a more homogeneous population of immature
progenitor cells as compared with bone marrow mononuclear
cells. Most of the cells became ICOSL-positive within a very
short period of time, and the levels of ICOSL were not further
up-regulated during later maturation toward DCs.
The CD34CD86 marrow cell population described by Ryn-
carz et al. (33) has antigen presenting capacity and mediates
allostimulation of T lymphocytes. Blocking ICOS:ICOSL inter-
action reduced the amount of T cell stimulation in both alloan-
tigenic assay and antigen-specific assays (7). The present work
suggests that ICOSL may also be important for the antigen
presenting capacity of immature myeloid cells. Stimulation of
purified CD34 cells with TNF- for 12 h generated a popula-
tion of cells that expressed ICOSL but neither CD80 nor CD86.
These TNF-activated CD34 cells are potent stimulators in an
alloantigen-specific MLR, suggesting that the CD28 costimula-
tory pathway is not necessary for ICOSL costimulation. Indeed,
Yoshinaga and colleagues (5) found that T cells from CD28/
mice still could be stimulated via ICOSL. Preventing ICOSL
expression by cocultivation of the cells in the presence of NF-B
inhibitors reduced the allostimulatory capacity of the cells by
50%. A reduction down to background levels was found by
adding ICOSIg. In agreement with the observed phenotype,
CD152Ig was less effective than ICOSIg in this experimental
set-up. However, we were not able to “freeze” the cells at this
differentiation stage, where they express ICOSL but not CD80
and CD86. Thus, it is likely that during the culture time some
expression of CD80/86 was induced. Interestingly, when using
mature monocytes or DC as antigen presenting cells, we had
detected a 50% reduction of T cell stimulation by ICOSIg, but a
complete inhibition by CD152Ig (7).
In our experiments TNF- was the key regulator of ICOSL
expression. In mammalian cells triggering of TNF receptor-I
initiates activation of IB kinase and p38 mitogen-activated
protein kinase, resulting in increased activity of the transcrip-
tion factors NF-B and AP-1 (34). The TNF-mediated NF-B
induction and the complete inhibition of ICOSL expression by
all three inhibitors of NF-B activation clearly show that the
TNF-induced ICOSL up-regulation is mainly mediated via the
NF-B pathway. This observation fits with the finding that
TPA can induce ICOSL expression as efficiently as TNF- (Fig.
4C). These results altogether suggest a very fast TNF-induced
and NF-B-dependent up-regulation of ICOSL, but not of the
CD152-binding molecules CD80/CD86, on CD34 hematopoi-
etic precursor cells. ICOSL and CD80/CD86 are also differently
regulated in mature monocytes where both antigens are super-
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induced by IFN-, but by distinct signaling pathways (7).
Among several TNF--induced genes that are regulated by
NF-B/Rel transcription, Swallow et al. (10) recently isolated a
gene (B7h) that is a close homologue of CD80/CD86 and almost
certainly is the murine homologue of ICOSL (5, 12). Murine
ICOSL is induced in 3T3 cells and in embryonic fibroblasts
upon TNF- treatment, and is up-regulated in peripheral tis-
sue under the influence of lipopolysaccharide, a potent activa-
tor of TNF-. By analogy to these findings, we show that
induction of ICOSL expression and its signaling pathway differ
in the various antigen presenting cells types investigated. In
our previous study, we could show that ICOSL expression on
monocytes was dependent on stimulation with IFN- but not
TNF-, IFN-, lipopolysaccharide, or phorbol 12-myristate 13-
acetate (7). Signaling pathways after IFN- stimulation specif-
ically involved protein kinase C but not NF-B activation, the
protein kinase C inhibitor staurosporine could only block the
IFN--mediated ICOSL up-regulation but not that of CD152
binding molecules. In contrast, in the present study, we now
demonstrate that induction of ICOSL expression on purified
CD34 progenitor cells is dependent on stimulation by TNF-
and phorbol esters and is mediated mainly by NF-B. Expres-
sion of ICOSL on mature, monocyte-derived DCs seems to be
independent of TNF- or lipopolysaccharide (7) and at a certain
stage of DC maturation may even inhibit ICOSL expression, as
demonstrated by others (13, 14).
Further experiments should reveal if efficient costimulation
in early hematopoietic precursors requires sequential expres-
sion of the various costimulatory molecules. Furthermore, it
would be important to find out whether memory T cells pref-
erentially use this costimulatory molecule that is constitutively
expressed on different types of antigen presenting cells, as
suggested by a recent work of Wallin et al. for CD8 CTL (20).
Finally, it will be important to analyze whether ICOSL plays
a role in regulating hemopoiesis. Its early expression before
CD80/CD86 may suggest that this molecule has a function
beyond simply stimulating activated T cells. Functional assays
of colony forming cells and distribution studies in pathological
conditions such as autoimmune cytopenias or transplant rejec-
tion will possibly help to clarify the role of this molecule.
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